Researchers at Israel’s Weizmann Institute of Science have genetically modified Nicotiana benthamiana tobacco plants to simultaneously produce five major psychedelic tryptamines — psilocybin and psilocin from mushrooms, DMT from ayahuasca plants, and bufotenin plus 5-MeO-DMT from toad venom — by transplanting biosynthetic gene pathways from their natural sources into a single fast-growing crop platform. The plants also generated novel derivative compounds and non-natural analogs, offering a proof-of-concept for scalable, sustainable psychedelic production that bypasses wild harvesting pressures on endangered species and complex chemical synthesis. Published in Science Advances, the work leveraged tobacco’s abundant tryptophan precursor and high biomass yield, achieving detectable levels of all five compounds concurrently despite pathway competition for shared metabolic resources.

The engineering combined nine key genes: PvTDC2 and PvNMT1 from Psychotria viridis for DMT, fungal enzymes for psilocybin/psilocin conversion, toad-derived pathways for bufotenin/5-MeO-DMT, plus rice and cress enzymes for optimization. AlphaFold3 AI predicted and fixed a bottleneck enzyme structure, boosting 5-MeO-DMT output 40-fold. While simultaneous production yields were lower due to resource competition, individual pathway optimization hit research-viable levels, and the sterile genetic design prevents environmental escape or inheritance. Lead developers Asaph Aharoni and Jonathan Berman frame this as a “biological factory” for therapeutics targeting depression, anxiety, and PTSD, where rising clinical demand collides with supply limits from regulated synthesis and overharvested naturals.

This converges multiple psychedelic biosyntheses into one crop, sidestepping the regulatory and scalability hurdles of microbial or synthetic production while preserving Indigenous sourcing traditions through lab alternatives. Tobacco’s lab-friendly growth cycle is weeks versus months for naturals, and it positions it as an ideal chassis, with potential expansion to other tryptamines or delivery-optimized analogs. The derivative compounds surfaced suggest untapped medicinal diversity for structure-activity testing.

Scientists Just Engineered Tobacco Plants To Produce 5 Psychedelics At Once, Including Psilocybin, DMT, Bufotenin, And Toad Venoms 🍂🍄🐸